UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Array BioPharma on MKE Program Potential - Array Technologies (NASDAQ:ARRY)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Monday, Jefferies analyst Eun K. Yang reiterated a Buy rating on Array BioPharma (NASDAQ: ARRY), and raised the price target from $6.50 to $7.00.In the report, Jefferies noted, “Recent FDA approval of GSK's Mekinist (trametinib) for melanoma validates therapeutic potential of the MEK inhibitor class. With planned multiple Ph3 initiations from ARRY's partnered two MEK programs (e.g., selumetinib with AZN and MEK-162 with NVS) in 2013, we view progress in partnered programs will likely drive valuation upside from current levels.”Array BioPharma closed on Friday at $5.84.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!